Osimertinib is the first third-generation EGFR-TKI approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for metastatic NSCLC patients with EGFR p.T790M mutation (30). This evidence concerns the gene EGFR and non-small cell lung carcinoma.